分化抗原簇63在非小细胞肺癌中的表达及临床意义

目的检测分化抗原簇63(cluster of differentiation 63,CD63)在非小细胞肺癌(non-small-cell lung cancer,NSCLC)组织中的表达水平与临床特征和生存的相关性。方法收集2013年6月至2015年1月在安阳市第二人民医院接受手术治疗的NSCLC患者126例,收集患者的一般临床资料和肿瘤组织样品;免疫组化实验检测NSCLC组织中CD63的表达水平,将其分为CD63高表达组和CD63低表达组;卡方检验分析CD63的表达与患者临床特征的相关性;Kaplan-Meier分析方法绘制生存曲线,Log-rank检验比较CD63高表达和低表达组的生存率;Cox回归模型进行单因素及多因素分析影响患者预后的独立危险因素。结果CD63在NSCLC组织中的高表达率为55.6%(70/126),低表达率为44.4%(56/126);CD63低表达组肿瘤分期T 3-T 4期、淋巴转移阳性和TNM分期Ⅲ期患者的比例均高于CD63高表达组;CD63低表达组5年中位生存时间和PFS均低于CD63高表达组(log-rank=5.272,P=0.022;log-rank=6.813,P=0.009);肿瘤分期、淋巴结转移、TNM分期Ⅲ-Ⅳ期和CD63低表达均为NSCLC患者预后不良的独立危险因素。结论CD63低表达与NSCLC患者的肿瘤分期、淋巴结转移、TNM分期和预后相关。

Expression of differentiation antigen cluster 63 in non-small cell lung cancer and its clinical significance

Objective To detect the correlation between the expression level of cluster 63 of CD63 in non-small-cell lung cancer(NSCLC)tissue and clinical features and survival.Methods A total of 126 NSCLC patients who underwent surgical treatment in our hospital from June 2013 to January 2015 were collected,and the general clinical data and tumor tissue samples of the patients were collected.CD63 expression level in NSCLC tissue was detected by immunohistochemical experiment,and it was divided into the high expression group and the low expression group.Chi-square test was used to analyze the correlation between the expression of CD63 and clinical characteristics of patients.Kaplan-Meier analysis method was used to draw the survival curve.Log-rank test was used to compare the survival rate of CD63 high and low expression groups.The cox regression model performed univariate and multivariate analysis of independent risk factors affecting patient prognosis.Results The high expression rate of CD63 in NSCLC tissues was 55.6%(70/126),and the low expression rate was 44.4%(56/126).The proportion of patients with T 3-T 4 stage,positive lymphatic metastasis,andⅢstage of TNM stage in the CD63 low expression group was higher than that in the CD63 high expression group.The 5-year median survival time and PFS of the CD63 low expression group were lower than that of the CD63 high expression group(log-rank=5.272,P=0.022;log-rank=6.813,P=0.009).Tumor stage,lymph node metastasis,TNM stageⅢ-Ⅳ,and low expression of CD63 were all independent risk factors for the prognosis of patients with NSCLC.Conclusion Low CD63 expression is associated with tumor stage,lymph node metastasis,TNM stage and prognosis in NSCLC patients.